PharmaEssentia (TPE: 6446), a leading global biopharmaceutical company dedicated to innovative therapies for significant human diseases, proudly announces that it has received a historic score of 66 in the 2024 S&P Global Corporate Sustainability Assessment (CSA), along with an ESG score of 69 (out of a maximum of 100). This marks an impressive increase of 16 points from the previous year, underscoring the company’s substantial progress in global sustainability initiatives. The strategic planning and execution of PharmaEssentia’s  five-year sustainability ESG development roadmap have demonstrated exceptional management performance.

 Industry Benchmark Comparison 

 PharmaEssentia’s sustainability performance has gained widespread recognition within the biopharmaceutical industry. Comparisons with other leading companies indicate that PharmaEssentia excels particularly in the social and governance dimensions: 

   PharmaEssentia’s  CSA score of 66 places it just 4 points behind the highest scorer, Grifols, at 70, and only 3 points behind renowned peers such as Biogen and AbbVie, both scoring 69. 

   Notably, PharmaEssentia achieved an outstanding score of 72 in the social dimension, reflecting its remarkable contributions to healthcare and talent management.

Significance of CSA and ESG Scores 

 The S&P Global Corporate Sustainability Assessment (CSA) and ESG scores assist investors in understanding a company's performance in environmental, social, and governance aspects. The CSA score is based on self-disclosed data from companies, emphasizing the quality and transparency of sustainability issues. The ESG score encompasses publicly available data, media reports, and model assessments, comparing a company’s performance in these areas with peers and focusing on its ability to manage risks and opportunities. 

 PharmaEssentia’s exemplary performance in the social dimension reflects its significant contributions to global healthcare and human capital management. This is especially important for long-term investors, as high ESG scores typically indicate a company’s strength in managing risks, enhancing transparency, and fostering sustainable growth.

Key Factors Influencing the Investment Market 

 PharmaEssentia’s outstanding ESG performance has a positive impact on the investment market. Global investors are increasingly focused on corporate sustainability, particularly in the biopharmaceutical sector, where ESG performance influences not only a company’s reputation but also its financial health and risk management capabilities. Companies with high scores often attract more investment, particularly from funds focused on ESG criteria. 

 Looking Ahead 

 PharmaEssentia remains committed to advancing sustainability and enhancing its innovative capabilities and global healthcare contributions. As the company achieves more sustainability goals, it is expected to create greater value for all stakeholders in the future. 

Further ESG Information Contact

 PharmaEssentia Corp. Sustainability Center Senior Director Shu-Fen Li 

 Te l:+886 2 26557688 ext. 7839 

 Email : Shufen_li@pharmaessentia.com 

 ESG website : http://www.pharmaessentia-esg.com 

 About CSA and ESG Scores

 Corporate Sustainability Assessment (CSA): Based on self-disclosed data from companies and responses to the S&P Global questionnaire, the CSA evaluates performance on sustainability-related issues, emphasizing disclosure quality and transparency. 

 ESG Score: The ESG score provides a comprehensive indicator of a company’s ability to manage risks and opportunities across environmental, social, and governance.